Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Glioblastoma 115Gliosarcoma 53Brain Neoplasms 53Glioma 47Central Nervous System Neoplasms 30Astrocytoma 29Melanoma 26Oligodendroglioma 14Neuroblastoma 10Neoplasm Metastasis 9Recurrence 7Ependymoma 7Sarcoma 6Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Skin Neoplasms 5Sarcoma, Ewing 5Lymphoma 5Breast Neoplasms 5Spinal Cord Neoplasms 4Somatostatinoma 4Neuroectodermal Tumors, Primitive, Peripheral 4Medulloblastoma 4Colorectal Neoplasms 4Small Cell Lung Carcinoma 3Lung Neoplasms 3Gastrinoma 3Carcinoma, Islet Cell 3Uveal Melanoma 2Rhabdomyosarcoma 2

Interventions

pembrolizumab 37Paclitaxel 36Carboplatin 31Cyclophosphamide 22Albumin-Bound Paclitaxel 20atezolizumab 16130-nm albumin-bound paclitaxel 16Taxes 15Doxorubicin 15Cisplatin 13Capecitabine 13Nivolumab 10Docetaxel 8olaparib 7Gemcitabine 6Everolimus 6talazoparib 5durvalumab 5Magnetic Resonance Spectroscopy 5Biopsy 5Bevacizumab 5veliparib 4spartalizumab 4sacituzumab govitecan 4pegfilgrastim 4liposomal doxorubicin 4eribulin 4Specimen Handling 4Immunoglobulin G 4trilaciclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Triple Negative Breast Neoplasms × Temozolomide × Clear all
NCT03150810 2024-12-20

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

BeiGene

Phase 1 Completed
139 enrolled 36 charts
BreastGastrointestinalGynecologicHead & NeckSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡